BONE DENSITY VALUES 120 PERCENT OR GREATER THAN AGE MATCHED: POSSIBLE GROUP RISK FOR BREAST CANCER.

1999 ◽  
Vol 24 (3) ◽  
pp. 218
Author(s):  
R. P. Spencer
Keyword(s):  
Breast Cancer ◽  
Bone Density ◽  
Density Values

Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer

1989 ◽  
Vol 81 (14) ◽  
pp. 1086-1088 ◽  
Author(s):  
S. Turken ◽  
E. Siris ◽  
D. Seldin ◽  
E. Flaster ◽  
G. Hyman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Density

scholarly journals Effect of Integrated Ayurveda and Yoga Therapy (IAYT) on osteoporosis detected in breast cancer patient on remission- A single case study

2020 ◽  
Vol 1 (2) ◽  
pp. 23
Author(s):  
Satyam Tripathi ◽  
Megha Panchal ◽  
Nooraini Binti Aliyas
Keyword(s):  
Breast Cancer ◽  
Bone Density ◽  
Ductal Carcinoma ◽  
Single Case ◽  
Alternative Therapy ◽  
Breast Cancer Patients ◽  
Yoga Therapy ◽  
Holistic Treatment ◽  
Treatment Medication

This is a case study for invasive ductal carcinoma diagnosed in a patient aged 60 years in 2015. She went through chemotherapy and radiotherapy and was on remission in 2016. Bone density degeneration was the side effect from the breast cancer treatment. After trying the conventional treatment, she was not satisfied, she came to Union Yoga Ayurveda (UYA), Singapore. She came to clinic looking for alternative therapy to help her increase her bone density, cope up with weakness and overall mental and physical wellbeing. The patient was given holistic treatment of yoga and Ayurveda, involving patra pinda sweda (herbal compress) and picchu (herbal soaked gauze pieces). The yoga therapy involved asanas practise to increase strength, breathing and meditation for overall wellbeing. The patient was not on any other treatment/medication during the entire treatment. After uninterrupted therapy for six months there was an increase in her bone density along with increase in energy level. The patient case study is an attempt to provide yoga and Ayurveda as an alternative/supportive treatment for remission management osteoporosis from breast cancer patients.

Dual Energy X-Ray Absorptiometry-Based Assessment of Male Patients Using Standardized Bone Density Values and a National Reference Database

2007 ◽  
Vol 10 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Stefan Goemaere ◽  
Dirk Vanderschueren ◽  
Jean-Marc Kaufman ◽  
Jean-Yves Reginster ◽  
Yves Boutsen ◽  
...  
Keyword(s):  
Bone Density ◽  
Dual Energy ◽  
Reference Database ◽  
X Ray ◽  
National Reference ◽  
Density Values ◽  
Male Patients

The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer

2003 ◽  
Vol 114 (8) ◽  
pp. 653-659 ◽  
Author(s):  
Nancy C Greep ◽  
Armando E Giuliano ◽  
Nora M Hansen ◽  
Tami Taketani ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Bone Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer

Clinical potential of new antiestrogens.

1997 ◽  
Vol 15 (2) ◽  
pp. 840-852 ◽  
Author(s):  
W J Gradishar ◽  
V C Jordan
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Bone Density ◽  
Clinical Experience ◽  
Advanced Disease ◽  
Adjuvant Therapies ◽  
Laboratory Development ◽  
Medical Indications ◽  
Clinical Potential

PURPOSE Based on the data and clinical experience derived from tamoxifen usage, the properties of an ideal antiestrogen is described that could have applications as a breast cancer preventative agent, long-term adjuvant therdpy, or as a treatment for osteoporosis. Each of the new antiestrogens currently being tested is discussed in terms of laboratory development, toxicology, pharmacology, endocrinology, and clinical evaluation. And each new compound is assessed according to the properties of an ideal antiestrogen. METHODS A review of all published reports was facilitated by the use of Medline computer searches. RESULTS Numerous compounds are being evaluated in clinical trials and can be categorized as triphenylethylenes or tamoxifen analogs, pure antiestrogens, and targeted antiestrogens. Several of these compounds may have fewer uterotropic properties and greater effects on maintaining bone density compared with tamoxifen; however, the clinical experience (ie, patient-years of treatment) with any of these compounds is minimal. CONCLUSION Although many of these compounds appear promising, further evaluation will be necessary to determine the role these compounds may serve as preventive agents, adjuvant therapies, treatments for advanced disease, or other medical indications such as osteoporosis.

Discrepancies between vertebral bone density values: The least dense vertebra

Maturitas ◽  
2006 ◽  
Vol 53 (4) ◽  
pp. 476-482 ◽  
Author(s):  
A. Mylonakis ◽  
D. Hadjidakis ◽  
P. Katsavochristos ◽  
I.I. Androulakis ◽  
M. Sfakianakis ◽  
...  
Keyword(s):  
Bone Density ◽  
Vertebral Bone ◽  
Density Values

Patterns of care regarding adjuvant hormonal agents and treatment of bone health in postmenopausal women with breast cancer in community and academic centers before and after the availability of ATAC (Adjuvant Tamoxifen, Armidex or Combination) study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6621-6621 ◽  
Author(s):  
M. K. Tummala ◽  
M. Wajahath ◽  
M. Kotlarewsky ◽  
A. Aggarwal ◽  
D. Muller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Density ◽  
Bone Health ◽  
Health Management ◽  
Bone Fractures ◽  
Early Stage ◽  
Academic Center ◽  
Before And After ◽  
Vitamin D Supplements

6621 Background: Results from the ATAC trial comparing Tamoxifen to the Aromatase inhibitors (AIs) anastrozole in PM women with early stage breast cancer were initially presented in San Antonio, Texas, in December 2001. ASCO issued guidelines for the adjuvant use of AIs in 2002, updated in 2003. We compared patterns of usage of adjuvant hormonal agents and bone health management before and after availability of the ATAC data in community versus academic centers. Methods: We conducted a retrospective analysis of 432 patients between 1999–2005 from group practices affiliated with two large community hospitals and one academic center. Data were collected from tumor registries regarding demographics, first-line hormonal agent choice, and use of bone density studies, vitamin D/calcium supplements and bisphosphonates. Results: Demographics were identical in both groups before and after January 2002. Before 2002, 96% of the patients were prescribed Tamoxifen in both community and academic centers. After the initial presentation of the ATAC data, 55.08% (65/118) of patients from the community centers versus only 17.11% (19/111) from the academic center were prescribed AIs (p=0.0001). Of the 84 patients who received an AI after January 2002, similar proportions of patients had baseline bone density scans (38.5% community vs. 36.8% academic; p=0.89) and follow up annual/biannual scans (33 % vs. 32%; p=0.85). In addition, similar proportions of patients on AIs were prescribed calcium/vitamin D supplements (47.4% vs. 52.6%; p=0.69) and bisphosphonates (36.8% vs. 21.05%; p=0.20) in community and academic centers, respectively. Conclusions: Community oncologists adopted AIs into clinical practice sooner than academic physicians on the basis of unpublished clinical trial results, even before ASCO published guidelines. Although patients on AIs are deemed to be at higher risk for bone fractures, fewer than 40% were evaluated with baseline or surveillance bone density scans in both community and academic practices. Similar proportions of patients received calcium/vitamin D supplements or bisphosphonates among centers. No significant financial relationships to disclose.

Bone density changes during adjuvant aromatase inhibitor treatment in breast cancer patients: Single center experience

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11565-e11565
Author(s):  
M. Almatari ◽  
M. Moe ◽  
P. Ali ◽  
P. Willshaw
Keyword(s):  
Breast Cancer ◽  
Bone Density ◽  
Bone Loss ◽  
Cancer Patients ◽  
Bisphosphonate Therapy ◽  
Density Change ◽  
Close Monitoring ◽  
Breast Cancer Patients ◽  
Single Center Experience ◽  
Dxa Scans

e11565 Background: Adjuvant aromatase inhibitors (AI) therapy in breast cancer accelerates bone loss resulting in increased incidence of fracture. We evaluated the effect of AI on bone density changes among breast cancer patients. Method: A total of 85 patients who had adjuvant AI for more than 24 months and 3 Dual energy X-ray Absorptiometry (DXA) scans were included in this study. Annual bone density change was calculated and correlated with various risk and prognostic factors. Results: Adjuvant AI was given in up-front (50), sequential (15) and extended adjuvant (17) therapy settings, with a median duration of 31 months. Intervals between scans varied from 6 - 33 months (median = 13 months), 63 patients had baseline DXA scans undertaken within 6 months from start of AI. Bisphosphonate was prescribed to 35 patients during AI therapy according to local practice. Changes in bone density according to WHO classification is shown in the table. Annual bone density change in the spine at 2nd scan was (-9.2% to +11%, mean = -0.89±4.11), after 3rd scan, (-11.7% to +10.7%, mean = 0.021±3.84). In the group of patients who had adjuvant chemotherapy (59 patients), significant bone loss was seen in the patients who did not have bisphosphonate (n=39), (-0.011 in BMD, Mean=0.88±0.02) compared to those who had bisphosphonate (n=20), (0.036 in BMD, Mean=0.93±0.02). In the patients who did not have chemotherapy (n=26), no bone loss was seen whether bisphosphonate was used or not. No clinical bone fracture was reported among patients who had osteoporosis at baseline. Conclusions: The patients who had chemotherapy are more likely to lose bone density and close monitoring is required for bisphosphonate therapy. Bone loss is more significant in the lumbar spine compared to the hip. Following intervention with bisphosphonate, the rate of bone loss was reduced, and as a result only 2.3% of patients developed osteoporosis during AI treatment. AI can be safely given from the bone health point of view with the appropriate use of bisphosphonate. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document